<li>abiraterone<p>abiraterone increases levels of promethazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.</p></li><li>abobotulinumtoxina<p>promethazine increases effects of abobotulinumtoxina by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>aclidinium<p>aclidinium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>albiglutide<p>promethazine, albiglutide. Other (see comment). Use Caution/Monitor. 
Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.</p></li><li>albuterol<p>promethazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>alfentanil<p>promethazine and alfentanil both increase  sedation. Use Caution/Monitor.</p></li><li>alprazolam<p>promethazine and alprazolam both increase  sedation. Use Caution/Monitor.</p></li><li>amisulpride<p>amisulpride and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and amisulpride both increase  sedation. Use Caution/Monitor.</p></li><li>amitriptyline<p>promethazine and amitriptyline both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>promethazine and amitriptyline both increase  sedation. Use Caution/Monitor.</p></li><li>amobarbital<p>promethazine and amobarbital both increase  sedation. Use Caution/Monitor.</p></li><li>amoxapine<p>promethazine and amoxapine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and amoxapine both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>promethazine and amoxapine both increase  sedation. Use Caution/Monitor.</p></li><li>anticholinergic/sedative combos<p>anticholinergic/sedative combos decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>anticholinergic/sedative combos decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>apomorphine<p>promethazine and apomorphine both increase  sedation. Use Caution/Monitor.</p></li><li>arformoterol<p>promethazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>aripiprazole<p>aripiprazole and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>armodafinil<p>promethazine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>atracurium<p>atracurium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>atracurium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>atropine<p>atropine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>atropine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>atropine iv/im<p>promethazine increases effects of atropine iv/im by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>azelastine<p>azelastine and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>azithromycin<p>promethazine and azithromycin both increase  QTc interval. Use Caution/Monitor.</p></li><li>baclofen<p>promethazine and baclofen both increase  sedation. Use Caution/Monitor.</p></li><li>bambuterol<p>promethazine increases and bambuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>belladonna alkaloids<p>belladonna alkaloids decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>belladonna alkaloids decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>belladonna and opium<p>promethazine and belladonna and opium both increase  sedation. Use Caution/Monitor.<span><br><br></span>belladonna and opium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>belladonna and opium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>benperidol<p>benperidol and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and benperidol both increase  sedation. Use Caution/Monitor.</p></li><li>benzphetamine<p>promethazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, benzphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>benztropine<p>promethazine increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. .</p></li><li>brompheniramine<p>brompheniramine and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>buclizine<p>buclizine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>buclizine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of buclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>buprenorphine<p>promethazine and buprenorphine both increase  sedation. Use Caution/Monitor.</p></li><li>buprenorphine buccal<p>promethazine and buprenorphine buccal both increase  sedation. Use Caution/Monitor.</p></li><li>bupropion<p>bupropion will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>butabarbital<p>promethazine and butabarbital both increase  sedation. Use Caution/Monitor.</p></li><li>butalbital<p>promethazine and butalbital both increase  sedation. Use Caution/Monitor.</p></li><li>butorphanol<p>promethazine and butorphanol both increase  sedation. Use Caution/Monitor.</p></li><li>caffeine<p>promethazine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>carbinoxamine<p>carbinoxamine and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>carisoprodol<p>promethazine and carisoprodol both increase  sedation. Use Caution/Monitor.</p></li><li>chloral hydrate<p>promethazine and chloral hydrate both increase  sedation. Use Caution/Monitor.</p></li><li>chlordiazepoxide<p>promethazine and chlordiazepoxide both increase  sedation. Use Caution/Monitor.</p></li><li>chlorpheniramine<p>chlorpheniramine and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>chlorpromazine<p>chlorpromazine and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and chlorpromazine both increase  sedation. Use Caution/Monitor.</p></li><li>chlorzoxazone<p>promethazine and chlorzoxazone both increase  sedation. Use Caution/Monitor.</p></li><li>cigarette smoking<p>cigarette smoking decreases levels of promethazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine &amp; thioridazine, but may occur w/other phenothiazines.</p></li><li>cinnarizine<p>cinnarizine and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>cisatracurium<p>cisatracurium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>cisatracurium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>citalopram<p>citalopram and promethazine both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>clemastine<p>clemastine and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>clobazam<p>clobazam will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. <span><br><br></span>promethazine, clobazam. Other (see comment). Use Caution/Monitor. 
Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).</p></li><li>clomethiazole<p>promethazine and clomethiazole both increase  sedation. Use Caution/Monitor.</p></li><li>clomipramine<p>promethazine and clomipramine both increase  sedation. Use Caution/Monitor.</p></li><li>clonazepam<p>promethazine and clonazepam both increase  sedation. Use Caution/Monitor.</p></li><li>clonidine<p>clonidine, promethazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.</p></li><li>clorazepate<p>promethazine and clorazepate both increase  sedation. Use Caution/Monitor.</p></li><li>clozapine<p>clozapine and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and clozapine both increase  sedation. Use Caution/Monitor.</p></li><li>codeine<p>promethazine and codeine both increase  sedation. Use Caution/Monitor.</p></li><li>cyclizine<p>cyclizine and promethazine both increase  sedation. Use Caution/Monitor.<span><br><br></span>cyclizine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>cyclizine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>cyclobenzaprine<p>promethazine and cyclobenzaprine both increase  sedation. Use Caution/Monitor.<span><br><br></span>cyclobenzaprine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>cyclobenzaprine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>cyproheptadine<p>cyproheptadine and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>dantrolene<p>promethazine and dantrolene both increase  sedation. Use Caution/Monitor.</p></li><li>darifenacin<p>darifenacin decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>darifenacin decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>dasatinib<p>promethazine and dasatinib both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>desflurane<p>desflurane and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>desipramine<p>promethazine and desipramine both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>promethazine and desipramine both increase  sedation. Use Caution/Monitor.</p></li><li>desvenlafaxine<p>desvenlafaxine will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses &lt;100 mg</p></li><li>dexchlorpheniramine<p>dexchlorpheniramine and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>dexfenfluramine<p>promethazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, dexfenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>dexmedetomidine<p>promethazine and dexmedetomidine both increase  sedation. Use Caution/Monitor.</p></li><li>dexmethylphenidate<p>promethazine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>dextroamphetamine<p>promethazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, dextroamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>dextromoramide<p>promethazine and dextromoramide both increase  sedation. Use Caution/Monitor.</p></li><li>diamorphine<p>promethazine and diamorphine both increase  sedation. Use Caution/Monitor.</p></li><li>diazepam<p>promethazine and diazepam both increase  sedation. Use Caution/Monitor.</p></li><li>dicyclomine<p>dicyclomine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>dicyclomine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>diethylpropion<p>promethazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, diethylpropion. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>difenoxin hcl<p>promethazine and difenoxin hcl both increase  sedation. Use Caution/Monitor.</p></li><li>dimenhydrinate<p>dimenhydrinate and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>diphenhydramine<p>diphenhydramine and promethazine both increase  sedation. Use Caution/Monitor.<span><br><br></span>diphenhydramine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>diphenhydramine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>diphenoxylate hcl<p>promethazine and diphenoxylate hcl both increase  sedation. Use Caution/Monitor.</p></li><li>dipipanone<p>promethazine and dipipanone both increase  sedation. Use Caution/Monitor.</p></li><li>dobutamine<p>promethazine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, dobutamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>dolasetron<p>promethazine and dolasetron both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>dopamine<p>promethazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>dopexamine<p>promethazine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dosulepin<p>promethazine and dosulepin both increase  sedation. Use Caution/Monitor.</p></li><li>doxepin<p>promethazine and doxepin both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>promethazine and doxepin both increase  sedation. Use Caution/Monitor.</p></li><li>doxylamine<p>promethazine and doxylamine both increase  sedation. Use Caution/Monitor.</p></li><li>droperidol<p>droperidol and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and droperidol both increase  sedation. Use Caution/Monitor.</p></li><li>eliglustat<p>eliglustat increases levels of promethazine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of promethazine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>enflurane<p>enflurane and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>ephedrine<p>promethazine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, ephedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>ephedrine (pulmonary)<p>promethazine increases and ephedrine (pulmonary) decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .<span><br><br></span>promethazine, ephedrine (pulmonary). Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>epinephrine<p>promethazine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, epinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.<span><br><br></span>promethazine decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia.</p></li><li>epinephrine racemic<p>promethazine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia.</p></li><li>estazolam<p>promethazine and estazolam both increase  sedation. Use Caution/Monitor.</p></li><li>ethanol<p>promethazine and ethanol both increase  sedation. Use Caution/Monitor.</p></li><li>etomidate<p>etomidate and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>fenfluramine<p>promethazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, fenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>fentanyl<p>fentanyl, promethazine.
Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.</p></li><li>fentanyl intranasal<p>fentanyl intranasal, promethazine.
Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.</p></li><li>fentanyl iontophoretic transdermal system<p>fentanyl iontophoretic transdermal system, promethazine.
Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.</p></li><li>fentanyl transdermal<p>fentanyl transdermal, promethazine.
Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.</p></li><li>fentanyl transmucosal<p>fentanyl transmucosal, promethazine.
Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.</p></li><li>fesoterodine<p>fesoterodine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>fesoterodine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>flavoxate<p>flavoxate decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>flavoxate decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>flecainide<p>promethazine and flecainide both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>flibanserin<p>promethazine and flibanserin both increase  sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.</p></li><li>fluoxetine<p>promethazine and fluoxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>fluphenazine<p>fluphenazine and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and fluphenazine both increase  sedation. Use Caution/Monitor.</p></li><li>flurazepam<p>promethazine and flurazepam both increase  sedation. Use Caution/Monitor.</p></li><li>fluvoxamine<p>promethazine and fluvoxamine both increase  QTc interval. Use Caution/Monitor.</p></li><li>formoterol<p>promethazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>foscarnet<p>promethazine and foscarnet both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>fospropofol<p>promethazine and fospropofol both increase  sedation. Use Caution/Monitor.</p></li><li>glycopyrrolate<p>promethazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>glycopyrrolate inhaled<p>glycopyrrolate inhaled decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>glycopyrrolate inhaled decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>gotu kola<p>gotu kola increases effects of promethazine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.</p></li><li>guanabenz<p>guanabenz, promethazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.</p></li><li>guanfacine<p>guanfacine, promethazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.</p></li><li>haloperidol<p>haloperidol and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and haloperidol both increase  sedation. Use Caution/Monitor.</p></li><li>hawthorn<p>hawthorn increases effects of promethazine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.</p></li><li>henbane<p>henbane decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>henbane decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of henbane by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>hexobarbital<p>promethazine and hexobarbital both increase  sedation. Use Caution/Monitor.</p></li><li>homatropine<p>homatropine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>homatropine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of homatropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>hops<p>hops increases effects of promethazine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.</p></li><li>hyaluronidase<p>promethazine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. 
Comment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect.</p></li><li>hydrocodone<p>promethazine and hydrocodone both increase  sedation. Use Caution/Monitor.</p></li><li>hydromorphone<p>promethazine and hydromorphone both increase  sedation. Use Caution/Monitor.</p></li><li>hydroxyzine<p>hydroxyzine and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>hyoscyamine<p>hyoscyamine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>hyoscyamine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of hyoscyamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>hyoscyamine spray<p>promethazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>iloperidone<p>iloperidone and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and iloperidone both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>promethazine and iloperidone both increase  sedation. Use Caution/Monitor.</p></li><li>imipramine<p>promethazine and imipramine both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>promethazine and imipramine both increase  sedation. Use Caution/Monitor.</p></li><li>incobotulinumtoxina<p>promethazine increases effects of incobotulinumtoxina by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>ipratropium<p>ipratropium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>isoproterenol<p>promethazine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, isoproterenol. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>kava<p>kava increases effects of promethazine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.</p></li><li>ketamine<p>ketamine and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>ketotifen, ophthalmic<p>promethazine and ketotifen, ophthalmic both increase  sedation. Use Caution/Monitor.</p></li><li>lapatinib<p>promethazine and lapatinib both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>levalbuterol<p>promethazine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>levofloxacin<p>promethazine and levofloxacin both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>levorphanol<p>promethazine and levorphanol both increase  sedation. Use Caution/Monitor.</p></li><li>liraglutide<p>promethazine, liraglutide. Other (see comment). Use Caution/Monitor. 
Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.</p></li><li>lisdexamfetamine<p>promethazine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, lisdexamfetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>lithium<p>lithium, promethazine. Other (see comment). Use Caution/Monitor. 
Comment: Risk of neurotoxicity.  Multiple mechanisms involved.</p></li><li>lofepramine<p>promethazine and lofepramine both increase  sedation. Use Caution/Monitor.</p></li><li>lofexidine<p>promethazine and lofexidine both increase  sedation. Use Caution/Monitor.</p></li><li>loprazolam<p>promethazine and loprazolam both increase  sedation. Use Caution/Monitor.</p></li><li>lorazepam<p>promethazine and lorazepam both increase  sedation. Use Caution/Monitor.</p></li><li>lorcaserin<p>lorcaserin will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lormetazepam<p>promethazine and lormetazepam both increase  sedation. Use Caution/Monitor.</p></li><li>loxapine<p>loxapine and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and loxapine both increase  sedation. Use Caution/Monitor.</p></li><li>loxapine inhaled<p>loxapine inhaled and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and loxapine inhaled both increase  sedation. Use Caution/Monitor.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, promethazine. affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2B6 substrates. .</p></li><li>lumefantrine<p>lumefantrine will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lurasidone<p>lurasidone increases effects of promethazine by Other (see comment). Use Caution/Monitor. 
Comment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed.; potendial for additive CNS effects .</p></li><li>maprotiline<p>promethazine and maprotiline both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>promethazine and maprotiline both increase  sedation. Use Caution/Monitor.</p></li><li>marijuana<p>promethazine and marijuana both increase  sedation. Use Caution/Monitor.</p></li><li>meclizine<p>meclizine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>meclizine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>melatonin<p>promethazine and melatonin both increase  sedation. Use Caution/Monitor.</p></li><li>mepenzolate<p>mepenzolate decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>mepenzolate decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of mepenzolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>meperidine<p>promethazine and meperidine both increase  sedation. Use Caution/Monitor.</p></li><li>mephobarbital<p>promethazine and mephobarbital both increase  sedation. Use Caution/Monitor.</p></li><li>meprobamate<p>promethazine and meprobamate both increase  sedation. Use Caution/Monitor.</p></li><li>metaproterenol<p>promethazine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>metaxalone<p>promethazine and metaxalone both increase  sedation. Use Caution/Monitor.</p></li><li>methadone<p>promethazine and methadone both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>promethazine and methadone both increase  sedation. Use Caution/Monitor.</p></li><li>methamphetamine<p>promethazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, methamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>methocarbamol<p>promethazine and methocarbamol both increase  sedation. Use Caution/Monitor.</p></li><li>methoxsalen<p>methoxsalen, promethazine.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects.</p></li><li>methscopolamine<p>methscopolamine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>methscopolamine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of methscopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>methylenedioxymethamphetamine<p>promethazine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, methylenedioxymethamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>methylphenidate<p>promethazine increases and methylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>metoclopramide<p>promethazine and metoclopramide both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.</p></li><li>mianserin<p>promethazine and mianserin both increase  sedation. Use Caution/Monitor.</p></li><li>midazolam<p>promethazine and midazolam both increase  sedation. Use Caution/Monitor.</p></li><li>midodrine<p>promethazine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, midodrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>mifepristone<p>mifepristone will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.</p></li><li>mirabegron<p>mirabegron will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mirtazapine<p>promethazine and mirtazapine both increase  sedation. Use Caution/Monitor.</p></li><li>modafinil<p>promethazine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>morphine<p>promethazine and morphine both increase  sedation. Use Caution/Monitor.</p></li><li>motherwort<p>promethazine and motherwort both increase  sedation. Use Caution/Monitor.</p></li><li>moxonidine<p>promethazine and moxonidine both increase  sedation. Use Caution/Monitor.</p></li><li>nabilone<p>promethazine and nabilone both increase  sedation. Use Caution/Monitor.</p></li><li>nalbuphine<p>promethazine and nalbuphine both increase  sedation. Use Caution/Monitor.</p></li><li>norepinephrine<p>promethazine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, norepinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>nortriptyline<p>promethazine and nortriptyline both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>promethazine and nortriptyline both increase  sedation. Use Caution/Monitor.</p></li><li>ofloxacin<p>promethazine and ofloxacin both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>olanzapine<p>olanzapine and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and olanzapine both increase  sedation. Use Caution/Monitor.</p></li><li>onabotulinumtoxina<p>onabotulinumtoxina decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>onabotulinumtoxina decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of onabotulinumtoxina by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>opium tincture<p>promethazine and opium tincture both increase  sedation. Use Caution/Monitor.</p></li><li>orphenadrine<p>promethazine and orphenadrine both increase  sedation. Use Caution/Monitor.</p></li><li>oxazepam<p>promethazine and oxazepam both increase  sedation. Use Caution/Monitor.</p></li><li>oxybutynin<p>oxybutynin decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>oxybutynin decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>oxybutynin topical<p>oxybutynin topical decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>oxybutynin topical decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>oxybutynin transdermal<p>oxybutynin transdermal decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>oxybutynin transdermal decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>oxycodone<p>promethazine and oxycodone both increase  sedation. Use Caution/Monitor.</p></li><li>oxymorphone<p>promethazine and oxymorphone both increase  sedation. Use Caution/Monitor.</p></li><li>paliperidone<p>paliperidone and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>promethazine and paliperidone both increase  sedation. Use Caution/Monitor.</p></li><li>pancuronium<p>pancuronium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>pancuronium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of pancuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>papaveretum<p>promethazine and papaveretum both increase  sedation. Use Caution/Monitor.</p></li><li>papaverine<p>promethazine and papaverine both increase  sedation. Use Caution/Monitor.</p></li><li>paroxetine<p>promethazine and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>passion flower<p>passion flower increases effects of promethazine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.</p></li><li>pazopanib<p>promethazine and pazopanib both increase  QTc interval. Use Caution/Monitor.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b, promethazine. Other (see comment). Use Caution/Monitor. 
Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.</p></li><li>pentazocine<p>promethazine and pentazocine both increase  sedation. Use Caution/Monitor.</p></li><li>pentobarbital<p>promethazine and pentobarbital both increase  sedation. Use Caution/Monitor.</p></li><li>perampanel<p>perampanel and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>perphenazine<p>perphenazine and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and perphenazine both increase  sedation. Use Caution/Monitor.</p></li><li>phendimetrazine<p>promethazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, phendimetrazine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>phenelzine<p>phenelzine increases effects of promethazine by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Coadministration of phenelzine and antihistamines may result in additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .</p></li><li>phenobarbital<p>promethazine and phenobarbital both increase  sedation. Use Caution/Monitor.</p></li><li>phentermine<p>promethazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, phentermine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>phenylephrine<p>promethazine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, phenylephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>phenylephrine po<p>promethazine increases and phenylephrine po decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .<span><br><br></span>promethazine, phenylephrine po. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>pholcodine<p>promethazine and pholcodine both increase  sedation. Use Caution/Monitor.</p></li><li>pimozide<p>pimozide and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and pimozide both increase  sedation. Use Caution/Monitor.</p></li><li>pirbuterol<p>promethazine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>porfimer<p>promethazine, porfimer. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced photosensitivity.</p></li><li>posaconazole<p>promethazine and posaconazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>pralidoxime<p>pralidoxime decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>pralidoxime decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of pralidoxime by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>primidone<p>promethazine and primidone both increase  sedation. Use Caution/Monitor.</p></li><li>procarbazine<p>procarbazine, promethazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Excessive sedation.</p></li><li>prochlorperazine<p>prochlorperazine and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and prochlorperazine both increase  sedation. Use Caution/Monitor.</p></li><li>propafenone<p>propafenone will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>propantheline<p>propantheline decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>propantheline decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>propofol<p>propofol and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>propylhexedrine<p>promethazine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, propylhexedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>protriptyline<p>promethazine and protriptyline both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>promethazine and protriptyline both increase  sedation. Use Caution/Monitor.</p></li><li>pseudoephedrine<p>promethazine increases and pseudoephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>quazepam<p>promethazine and quazepam both increase  sedation. Use Caution/Monitor.</p></li><li>quetiapine<p>promethazine and quetiapine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and quetiapine both increase  sedation. Use Caution/Monitor.</p></li><li>quinidine<p>quinidine will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>ramelteon<p>promethazine and ramelteon both increase  sedation. Use Caution/Monitor.</p></li><li>ranolazine<p>promethazine and ranolazine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>rapacuronium<p>rapacuronium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>rapacuronium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of rapacuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>risperidone<p>promethazine and risperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and risperidone both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>promethazine and risperidone both increase  sedation. Use Caution/Monitor.</p></li><li>rocuronium<p>rocuronium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>rocuronium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of rocuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>salmeterol<p>promethazine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>scopolamine<p>scopolamine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>scopolamine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of scopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>scullcap<p>promethazine and scullcap both increase  sedation. Use Caution/Monitor.</p></li><li>secobarbital<p>promethazine and secobarbital both increase  sedation. Use Caution/Monitor.</p></li><li>sertindole<p>promethazine and sertindole both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and sertindole both increase  sedation. Use Caution/Monitor.</p></li><li>sevoflurane<p>sevoflurane and promethazine both increase  sedation. Use Caution/Monitor.</p></li><li>shepherd's purse<p>promethazine and shepherd's purse both increase  sedation. Use Caution/Monitor.</p></li><li>smoking<p>smoking decreases levels of promethazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine &amp; thioridazine, but may occur w/other phenothiazines.</p></li><li>solifenacin<p>solifenacin decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>solifenacin decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>sufentanil<p>promethazine and sufentanil both increase  sedation. Use Caution/Monitor.</p></li><li>sulfamethoxazole<p>promethazine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>sulpiride<p>promethazine and sulpiride both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and sulpiride both increase  sedation. Use Caution/Monitor.</p></li><li>tapentadol<p>promethazine and tapentadol both increase  sedation. Use Caution/Monitor.</p></li><li>telavancin<p>promethazine and telavancin both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>telithromycin<p>promethazine and telithromycin both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>temazepam<p>promethazine and temazepam both increase  sedation. Use Caution/Monitor.</p></li><li>terbutaline<p>promethazine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>terfenadine<p>promethazine and terfenadine both increase  sedation. Use Caution/Monitor.</p></li><li>tetrabenazine<p>promethazine and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.</p></li><li>thioridazine<p>promethazine and thioridazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and thioridazine both increase  sedation. Use Caution/Monitor.</p></li><li>thiothixene<p>promethazine and thiothixene both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and thiothixene both increase  sedation. Use Caution/Monitor.</p></li><li>tiotropium<p>tiotropium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>tiotropium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>tobacco use<p>tobacco use decreases levels of promethazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine &amp; thioridazine, but may occur w/other phenothiazines.</p></li><li>tolterodine<p>tolterodine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>tolterodine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of tolterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>topiramate<p>promethazine and topiramate both increase  sedation. Modify Therapy/Monitor Closely.</p></li><li>tramadol<p>promethazine and tramadol both increase  sedation. Use Caution/Monitor.</p></li><li>trazodone<p>promethazine and trazodone both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>promethazine and trazodone both increase  sedation. Use Caution/Monitor.</p></li><li>triazolam<p>promethazine and triazolam both increase  sedation. Use Caution/Monitor.</p></li><li>triclofos<p>promethazine and triclofos both increase  sedation. Use Caution/Monitor.</p></li><li>trifluoperazine<p>promethazine and trifluoperazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and trifluoperazine both increase  sedation. Use Caution/Monitor.</p></li><li>trihexyphenidyl<p>trihexyphenidyl decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive anticholinergic effects.</p></li><li>trimethoprim<p>promethazine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>trimipramine<p>promethazine and trimipramine both increase  sedation. Use Caution/Monitor.</p></li><li>tropisetron<p>promethazine and tropisetron both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>trospium chloride<p>trospium chloride decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>trospium chloride decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of trospium chloride by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>tubocurarine<p>tubocurarine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>tubocurarine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of tubocurarine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>valerian<p>valerian increases effects of promethazine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.</p></li><li>vecuronium<p>vecuronium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>vecuronium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>venlafaxine<p>promethazine and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>voriconazole<p>promethazine and voriconazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>xylometazoline<p>promethazine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, xylometazoline. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>yohimbine<p>promethazine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>promethazine, yohimbine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines.  Interaction more likely in certain predisposed pts. only.</p></li><li>ziconotide<p>promethazine and ziconotide both increase  sedation. Use Caution/Monitor.</p></li><li>ziprasidone<p>promethazine and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and ziprasidone both increase  sedation. Use Caution/Monitor.</p></li><li>zotepine<p>promethazine and zotepine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and zotepine both increase  sedation. Use Caution/Monitor.</p></li>